Cargando…

ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway

Diabetic nephropathy (DN) is one of the main causes of renal fibrosis and is associated with high morbidity and mortality. Traditional Chinese Medicine (TCM) therapy has a long history of usage in a clinical setting and its usage is increasing. ErHuang Formula (EHF), a Chinese herbal compound, has b...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yu-Li, Jiang, Yi-ping, Li, Xiao-Qin, Wang, Su-Juan, Ma, Ming-Hua, Zhang, Chun-Yan, Zhu, Jian-Yong, Rahman, Khalid, Zhang, Li-Jun, Luan, Xin, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993046/
https://www.ncbi.nlm.nih.gov/pubmed/32038260
http://dx.doi.org/10.3389/fphar.2019.01596
_version_ 1783492955062927360
author Shen, Yu-Li
Jiang, Yi-ping
Li, Xiao-Qin
Wang, Su-Juan
Ma, Ming-Hua
Zhang, Chun-Yan
Zhu, Jian-Yong
Rahman, Khalid
Zhang, Li-Jun
Luan, Xin
Zhang, Hong
author_facet Shen, Yu-Li
Jiang, Yi-ping
Li, Xiao-Qin
Wang, Su-Juan
Ma, Ming-Hua
Zhang, Chun-Yan
Zhu, Jian-Yong
Rahman, Khalid
Zhang, Li-Jun
Luan, Xin
Zhang, Hong
author_sort Shen, Yu-Li
collection PubMed
description Diabetic nephropathy (DN) is one of the main causes of renal fibrosis and is associated with high morbidity and mortality. Traditional Chinese Medicine (TCM) therapy has a long history of usage in a clinical setting and its usage is increasing. ErHuang Formula (EHF), a Chinese herbal compound, has been clinically used in treating DN for more than 30 years. However, its mechanism of action is still unknown. This study was conducted to evaluate the effect of EHF on renal fibrosis in a DN rat model and explore its underlying mechanism. The DN rat model was established by high-sugar-fat diet combined with a single intraperitoneal injection of streptozotocin (STZ), and EFH extract (4, 2, 1 g/kg d(−1)) was administered orally for 8 weeks. The biochemical parameters (blood glucose, weight, Scr, BUN, UA, U-Alb and UAE) were analyzed. The pathological changes in renal tissue were observed by histological staining with H&E and Masson. The effect of EHF on the proliferation of NRK-49F cells was examined by CCK-8 assay and the levels of several inflammation and fibrosis related cytokines (IL-6, TNF-α, TGF-β1, Collagen I/III, MMP2/9) in serum and NRK-49F cell culture supernatants were detected by enzyme-linked immunoassay (ELISA). The mRNA levels of CXCL6, CXCR1, Collagen I/III, MMP2/9 in renal tissue were also measured by quantitative RT-PCR. Furthermore, the protein expression of PCNA, Collagen I/III, MMP2/9, CXCL6, CXCR1, p-STAT3, STAT3 in renal tissue and NRK-49F cells were determined by western blot. EHF improved the abnormal biochemical parameters and ameliorated the abnormal histology and fibrosis of renal tissue in a dose-dependent manner. EHF inhibited NRK-49F proliferation and decreased the expressions of inflammation and fibrosis related factors both in vitro and in vivo. Interestingly, the levels of Collagen I/III, PCNA, MMP2/9 and p-STAT3 were positively correlated with CXCL6. The amelioration of renal fibrosis in DN by EHF is related to CXCL6/JAK/STAT3 signal pathway, which is associated with inflammation and fibrosis of the tissue. These findings may have clinical implications for the treatment of DN.
format Online
Article
Text
id pubmed-6993046
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69930462020-02-07 ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway Shen, Yu-Li Jiang, Yi-ping Li, Xiao-Qin Wang, Su-Juan Ma, Ming-Hua Zhang, Chun-Yan Zhu, Jian-Yong Rahman, Khalid Zhang, Li-Jun Luan, Xin Zhang, Hong Front Pharmacol Pharmacology Diabetic nephropathy (DN) is one of the main causes of renal fibrosis and is associated with high morbidity and mortality. Traditional Chinese Medicine (TCM) therapy has a long history of usage in a clinical setting and its usage is increasing. ErHuang Formula (EHF), a Chinese herbal compound, has been clinically used in treating DN for more than 30 years. However, its mechanism of action is still unknown. This study was conducted to evaluate the effect of EHF on renal fibrosis in a DN rat model and explore its underlying mechanism. The DN rat model was established by high-sugar-fat diet combined with a single intraperitoneal injection of streptozotocin (STZ), and EFH extract (4, 2, 1 g/kg d(−1)) was administered orally for 8 weeks. The biochemical parameters (blood glucose, weight, Scr, BUN, UA, U-Alb and UAE) were analyzed. The pathological changes in renal tissue were observed by histological staining with H&E and Masson. The effect of EHF on the proliferation of NRK-49F cells was examined by CCK-8 assay and the levels of several inflammation and fibrosis related cytokines (IL-6, TNF-α, TGF-β1, Collagen I/III, MMP2/9) in serum and NRK-49F cell culture supernatants were detected by enzyme-linked immunoassay (ELISA). The mRNA levels of CXCL6, CXCR1, Collagen I/III, MMP2/9 in renal tissue were also measured by quantitative RT-PCR. Furthermore, the protein expression of PCNA, Collagen I/III, MMP2/9, CXCL6, CXCR1, p-STAT3, STAT3 in renal tissue and NRK-49F cells were determined by western blot. EHF improved the abnormal biochemical parameters and ameliorated the abnormal histology and fibrosis of renal tissue in a dose-dependent manner. EHF inhibited NRK-49F proliferation and decreased the expressions of inflammation and fibrosis related factors both in vitro and in vivo. Interestingly, the levels of Collagen I/III, PCNA, MMP2/9 and p-STAT3 were positively correlated with CXCL6. The amelioration of renal fibrosis in DN by EHF is related to CXCL6/JAK/STAT3 signal pathway, which is associated with inflammation and fibrosis of the tissue. These findings may have clinical implications for the treatment of DN. Frontiers Media S.A. 2020-01-24 /pmc/articles/PMC6993046/ /pubmed/32038260 http://dx.doi.org/10.3389/fphar.2019.01596 Text en Copyright © 2020 Shen, Jiang, Li, Wang, Ma, Zhang, Zhu, Rahman, Zhang, Luan and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Shen, Yu-Li
Jiang, Yi-ping
Li, Xiao-Qin
Wang, Su-Juan
Ma, Ming-Hua
Zhang, Chun-Yan
Zhu, Jian-Yong
Rahman, Khalid
Zhang, Li-Jun
Luan, Xin
Zhang, Hong
ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway
title ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway
title_full ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway
title_fullStr ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway
title_full_unstemmed ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway
title_short ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway
title_sort erhuang formula improves renal fibrosis in diabetic nephropathy rats by inhibiting cxcl6/jak/stat3 signaling pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993046/
https://www.ncbi.nlm.nih.gov/pubmed/32038260
http://dx.doi.org/10.3389/fphar.2019.01596
work_keys_str_mv AT shenyuli erhuangformulaimprovesrenalfibrosisindiabeticnephropathyratsbyinhibitingcxcl6jakstat3signalingpathway
AT jiangyiping erhuangformulaimprovesrenalfibrosisindiabeticnephropathyratsbyinhibitingcxcl6jakstat3signalingpathway
AT lixiaoqin erhuangformulaimprovesrenalfibrosisindiabeticnephropathyratsbyinhibitingcxcl6jakstat3signalingpathway
AT wangsujuan erhuangformulaimprovesrenalfibrosisindiabeticnephropathyratsbyinhibitingcxcl6jakstat3signalingpathway
AT maminghua erhuangformulaimprovesrenalfibrosisindiabeticnephropathyratsbyinhibitingcxcl6jakstat3signalingpathway
AT zhangchunyan erhuangformulaimprovesrenalfibrosisindiabeticnephropathyratsbyinhibitingcxcl6jakstat3signalingpathway
AT zhujianyong erhuangformulaimprovesrenalfibrosisindiabeticnephropathyratsbyinhibitingcxcl6jakstat3signalingpathway
AT rahmankhalid erhuangformulaimprovesrenalfibrosisindiabeticnephropathyratsbyinhibitingcxcl6jakstat3signalingpathway
AT zhanglijun erhuangformulaimprovesrenalfibrosisindiabeticnephropathyratsbyinhibitingcxcl6jakstat3signalingpathway
AT luanxin erhuangformulaimprovesrenalfibrosisindiabeticnephropathyratsbyinhibitingcxcl6jakstat3signalingpathway
AT zhanghong erhuangformulaimprovesrenalfibrosisindiabeticnephropathyratsbyinhibitingcxcl6jakstat3signalingpathway